Sharekhan's research report on Dr. Reddy’s Laboratories
With onset of new Omicron variant of Covid 19, demand for DRL’s Covid drugs including Sputnik vaccines is likely to improve. USFDA’s EUA for Molnupiravir could also likely have a positive rub off as DRL holds rights for Molnupiravir for India and other LMIC’s. DRL is committed to resolving the USFDA observations for Duvvada formulations plant and is confident of submitting timely responses. Strong product pipeline, pick up in base business to drive US sales and enable DRL to tide over competitive pressures while new launches, expanding penetration and pick up in existing portfolio including Covid basket to drive India sales.
Outlook
We re-iterate Buy recommendation on Dr Reddys Laboratories (DRL) with an unchanged PT of Rs 5900.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
Read More
